Department of Pathology, College of Korean Medicine, Sangji University, Wonju-si, Gangwon-do, 26339, Republic of Korea.
Department of Pathology, College of Korean Medicine, Sangji University, Wonju-si, Gangwon-do, 26339, Republic of Korea; Kyunghee University Medical Center, Kyunghee University, Seoul, 02447, Republic of Korea.
J Ethnopharmacol. 2020 Dec 5;263:113152. doi: 10.1016/j.jep.2020.113152. Epub 2020 Aug 2.
Sojadodamgangki-tang (SDG) is a traditional East-Asian herbal medicine mainly composed of Pinellia ternate (Thunb.) Makino, Perilla frutescens (L.) Britt and 10 kinds of medicinal herbs. It has been used to treat asthma and mucus secretion including lung and bronchi.
The aim of this study was to investigate the anti-inflammatory effects of Sojadodamgangki-tang (SDG) on allergic lung inflammation in vitro and in vivo as well as the underlying mechanisms.
We used an ovalbumin (OVA)-induced murine allergic airway inflammation model. Five groups of 8-week-old female BALB/C mice were divided into the following groups: saline control group, the vehicle (allergic) group that received OVA only, groups that received OVA and SDG (200 mg/kg or 400 mg/kg), and a positive control group that received OVA and Dexamethasone (5 mg/kg). In vitro experiments include T helper 2 (TH2) polarization system, murine macrophage cell culture, and human bronchial epithelial cell line (BEAS-2B) culture.
SDG administration reduced allergic airway inflammatory cell infiltration, especially of eosinophils, mucus production, Th2 cell activation, OVA-specific immunoglobulin E (IgE), and total IgE production. Moreover, the activation of alveolar macrophages, which leads to immune tolerance in the steady state, was promoted by SDG treatment. Interestingly, SDG treatment also reduced the production of alarmin cytokines by the human bronchial epithelial cell line BEAS-2B stimulated with urban particulate matter.
Our findings indicate that SDG has potential as a therapeutic drug to inhibit Th2 cell activation and promote alveolar macrophage activation.
大豆当甘姜汤(SDG)是一种主要由半夏(Pinellia ternate(Thunb.)Makino)、紫苏(Perilla frutescens(L.)Britt)和 10 种草药组成的传统东亚草药。它被用于治疗哮喘和包括肺和支气管在内的黏液分泌。
本研究旨在研究大豆当甘姜汤(SDG)对体外和体内变应性肺炎症的抗炎作用及其机制。
我们使用卵清蛋白(OVA)诱导的小鼠变应性气道炎症模型。将 5 组 8 周龄雌性 BALB/C 小鼠分为以下几组:生理盐水对照组、仅接受 OVA 的载体(变应性)组、接受 OVA 和 SDG(200mg/kg 或 400mg/kg)的组以及接受 OVA 和地塞米松(5mg/kg)的阳性对照组。体外实验包括辅助性 T 细胞 2(TH2)极化系统、鼠巨噬细胞培养和人支气管上皮细胞系(BEAS-2B)培养。
SDG 给药减少了变应性气道炎症细胞浸润,特别是嗜酸性粒细胞、黏液产生、TH2 细胞活化、OVA 特异性免疫球蛋白 E(IgE)和总 IgE 产生。此外,SDG 治疗促进了肺泡巨噬细胞的活化,这导致了在稳定状态下的免疫耐受。有趣的是,SDG 治疗还降低了人支气管上皮细胞系 BEAS-2B 受城市颗粒物刺激后警报素细胞因子的产生。
我们的研究结果表明,SDG 具有作为抑制 TH2 细胞活化和促进肺泡巨噬细胞活化的治疗药物的潜力。